Branko Braam
University of Alberta · UMC Utrecht, The Netherlands
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Branko Braam as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06920914 · Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKDUniversity of Alberta · not yet recruiting · Chronic Kidney Disease · principal investigator
- Ph4NCT05915286 · Diuretic Use in Hemodialysis Patients With Residual Renal FunctionUniversity of Alberta · terminated · End Stage Renal Disease on Dialysis · principal investigator
- N/ANCT03929471 · Target Weight Correction and Vascular Stiffness in Hemodialysis PatientsUniversity of Alberta · completed · Fluid Overload, Vascular Stiffness · principal investigator
- Ph3NCT00356733 · Mechanisms of Erythropoietin Action in the Cardiorenal SyndromeUMC Utrecht · completed · Heart Failure, Congestive, Renal Insufficiency, Chronic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:33 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.Ann Intern Med · 2009479 citationsRCR 13.8
- Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients.Crit Care Med · 2000161 citationsRCR 4.9
- Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology.Kidney Int · 1994129 citationsRCR 4.8
- 69 citationsRCR 2.0
- Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance.J Card Fail · 201169 citationsRCR 2.5
- Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients.Eur J Heart Fail · 201067 citationsRCR 2.1
- Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.J Am Heart Assoc · 201921 citationsRCR 1.2
- Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study.J Nephrol · 201017 citationsRCR 0.6
- Neutrophil gelatinase-associated lipocalin (NGAL) in chronic cardiorenal failure is correlated with endogenous erythropoietin levels and decreases in response to low-dose erythropoietin treatment.Kidney Blood Press Res · 201217 citationsRCR 0.6
- 15 citationsRCR 0.5